Chapman PB - Search Results

1

Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.

Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Nasi ML, et al. Among authors: chapman pb. Melanoma Res. 1997 Aug;7 Suppl 2:S155-62. Melanoma Res. 1997. PMID: 9578432 Review.

2

Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.

Bajorin DF, Chapman PB, Wong GY, Cody BV, Cordon-Cardo C, Dantes L, Templeton MA, Scheinberg D, Oettgen HF, Houghton AN. Bajorin DF, et al. Among authors: chapman pb. Melanoma Res. 1992 Dec;2(5-6):355-62. doi: 10.1097/00008390-199212000-00009. Melanoma Res. 1992. PMID: 1292783

3

Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.

Chapman PB, Yuasa H, Houghton AN. Chapman PB, et al. J Immunol. 1990 Aug 1;145(3):891-8. J Immunol. 1990. PMID: 1695649

4

Phase II trial of cisplatin and etoposide in patients with metastatic melanoma.

Eton O, Bajorin DF, Chapman PB, Cody BV, Houghton AN. Eton O, et al. Among authors: chapman pb. Invest New Drugs. 1991 Feb;9(1):101-3. doi: 10.1007/BF00194558. Invest New Drugs. 1991. PMID: 2026478 Clinical Trial.

5

Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Chapman PB, Houghton AN. Chapman PB, et al. J Clin Invest. 1991 Jul;88(1):186-92. doi: 10.1172/JCI115276. J Clin Invest. 1991. PMID: 2056117 Free PMC article.

6

Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.

Chapman PB, Lonberg M, Houghton AN. Chapman PB, et al. Cancer Res. 1990 Mar 1;50(5):1503-9. Cancer Res. 1990. PMID: 2105840

7

Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.

Bajorin DF, Chapman PB, Wong G, Coit DG, Kunicka J, Dimaggio J, Cordon-Cardo C, Urmacher C, Dantes L, Templeton MA, et al. Bajorin DF, et al. Among authors: chapman pb. Cancer Res. 1990 Dec 1;50(23):7490-5. Cancer Res. 1990. PMID: 2253196 Clinical Trial.

8

Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside.

Houghton AN, Bajorin DF, Lonberg M, Chapman P. Houghton AN, et al. Prog Clin Biol Res. 1989;288:383-90. Prog Clin Biol Res. 1989. PMID: 2654956 Clinical Trial. No abstract available.

9

Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside.

Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JE, Cordon-Cardo C, Buhrer C, Old LJ, Houghton AN. Welte K, et al. Among authors: chapman pb. J Immunol. 1987 Sep 15;139(6):1763-71. J Immunol. 1987. PMID: 2887619

10

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.

Chapman PB, Gillies SD, Houghton AN, Reilly RM. Chapman PB, et al. Cancer Immunol Immunother. 1994 Sep;39(3):198-204. doi: 10.1007/BF01533387. Cancer Immunol Immunother. 1994. PMID: 7522964 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters